From: circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3
Parameters | Univariable logistic regression | Multivariable logistic regression | ||||
---|---|---|---|---|---|---|
OR | 95% CI | P | OR | 95% CI | P | |
Age (years) | 0.993 | 0.931–1.059 | 0.830 |  |  |  |
PSA pre-treatment (ng/ml) | 0.999 | 0.994–1.004 | 0.596 |  |  |  |
Prostate volume (ml) | 0.965 | 0.890–1.047 | 0.395 |  |  |  |
PSA post-treatment (ng/ml) | 0.072 | 0.007–0.719 | 0.025 | 0.033 | 0.002–0.609 | 0.022 |
Tumor max diameter on MRI | 0.792 | 0.504–1.244 | 0.311 |  |  |  |
PI-RADS | ||||||
 4 vs. 3 | 0.333 | 0.043–2.564 | 0.291 |  |  |  |
 5 vs. 3 | 0.538 | 0.082–3.526 | 0.519 |  |  |  |
Clinical T stage | ||||||
 T3a vs. T4 | 1.944 | 0.383–9.883 | 0.423 |  |  |  |
 T3b vs. T4 | 0.942 | 0.193–4.595 | 0.941 |  |  |  |
ISUP grade at biopsy | ||||||
 2 vs 1 | 0.089 | 0.009–0.839 | 0.035 | 0.137 | 0.007–2.824 | 0.198 |
 3 vs 1 | 0.667 | 0.076–5.878 | 0.715 | 0.538 | 0.027–10.591 | 0.684 |
 4 vs 1 | 0.232 | 0.038–1.401 | 0.111 | 0.331 | 0.026–4.205 | 0.394 |
 5 vs 1 | 0.400 | 0.057–2.800 | 0.356 | 0.423 | 0.026–6.750 | 0.542 |
circCYP24A1 expression | ||||||
 Low vs High | 0.135 | 0.045–0.407 | < 0.001 | 0.165 | 0.038–0.723 | 0.017 |
miR-1301-3p expression | ||||||
 Low vs High | 3.000 | 1.117–8.058 | 0.029 | 1.096 | 0.252–4.766 | 0.903 |
ALDH1A3 expression | ||||||
 Low vs High | 0.347 | 0.130–0.926 | 0.035 | 0.426 | 0.099–1.832 | 0.251 |